TheStreet lowered shares of ProPhase Labs (NASDAQ:PRPH) from a c- rating to a d+ rating in a research report sent to investors on Tuesday, TheStreetRatingsTable reports.
NASDAQ:PRPH remained flat at $$2.07 during trading hours on Tuesday. The company’s stock had a trading volume of 900 shares, compared to its average volume of 9,033. The business has a 50-day moving average of $2.72. ProPhase Labs has a twelve month low of $2.01 and a twelve month high of $4.00.
ProPhase Labs (NASDAQ:PRPH) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.09) earnings per share (EPS) for the quarter. The business had revenue of $2.32 million for the quarter. ProPhase Labs had a negative net margin of 23.26% and a negative return on equity of 14.54%.
ProPhase Labs Company Profile
ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.
Read More: What does an outperform rating mean?
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.